| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,800 | 22,000 | 16:40 | |
| 21,800 | 22,000 | 16:41 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11. | SI-BONE, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11. | Needham lowers SI-BONE stock price target to $26 on pricing mix | 3 | Investing.com | ||
| 03.11. | Citizens reiterates SI-BONE stock rating on strong Q3 results | 2 | Investing.com | ||
| 03.11. | Canaccord reiterates SI-BONE stock rating on strong surgeon growth | 2 | Investing.com | ||
| 03.11. | Si-bone reaffirms 2026 revenue outlook as Onyx launch targets $5B annual market opportunity | 2 | Seeking Alpha | ||
| 03.11. | SI-BONE Q3 2026 Earnings Call Transcript | 2 | Benzinga.com | ||
| 02.11. | SI-BONE übertrifft Prognosen für das 3. Quartal 2026 - Aktie gerät dennoch unter Druck | 2 | Investing.com Deutsch | ||
| 02.11. | SI-BONE GAAP EPS of -$0.08 beats by $0.05, revenue of $55.7M beats by $0.39M | 3 | Seeking Alpha | ||
| SI-BONE Aktie jetzt für 0€ handeln | |||||
| 02.11. | SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance | 2 | GlobeNewswire (USA) | ||
| 02.11. | SI-BONE, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.10. | SI-BONE, Inc.: SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026 | 1 | GlobeNewswire (USA) | ||
| 28.09. | SI-BONE receives FDA clearance for spinal fusion system | 1 | Investing.com | ||
| 28.09. | SI-BONE, Inc.: SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx, Extending Its Compromised Bone Franchise Beyond the Pelvis | 244 | GlobeNewswire (Europe) | SANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised... ► Artikel lesen | |
| 11.09. | SI-BONE, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | SI-BONE, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | SI-BONE signals 2026 revenue of $231M-$233M as it plans Q4 launch of third breakthrough device | 4 | Seeking Alpha | ||
| 04.08. | SI-BONE Q2 2026 slides: revenue up 15%, shares fall on outlook | 5 | Investing.com | ||
| 03.08. | Earnings Call Transkript: SI-BONE übertrifft Q2-Prognosen, Aktie bricht nachbörslich dennoch ein | 2 | Investing.com Deutsch | ||
| 03.08. | SI-BONE GAAP EPS of -$0.09 beats by $0.06, revenue of $56M beats by $0.6M | 2 | Seeking Alpha | ||
| 03.08. | SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance | 257 | GlobeNewswire (Europe) | Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period)... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 14,560 | -1,29 % | Eckert & Ziegler Aktie: Isotopen-Boom lässt Analysten aufhorchen | Die starke Nachfrage nach radioaktiven Isotopen für die Krebstherapie sorgt bei Eckert & Ziegler für steigende Gewinne und positive Analystenstimmen. Berenberg erhöht nach den Quartalszahlen das Kursziel... ► Artikel lesen | |
| DRAEGERWERK | 117,20 | +1,21 % | DRÄGERWERK setzt Ziele hoch | Im kommenden Jahr will man Umsatz und Profitabilität deutlich steigern. Auf dem heutigen Kapitalmarkttag von DRÄGERWERK erklärte das Unternehmen, dass der Erlös 2030 dann rund 4,5 Mrd. Euro erreichen... ► Artikel lesen | |
| MEDTRONIC | 92,70 | +1,09 % | Medtronic: What Happens When Healthcare Technology Starts With People | From living rooms to operating rooms, human-centered design is informing the future of tech?Key takeawaysHuman-centered design at Medtronic uses patient, caregiver, and clinician insights to make medical... ► Artikel lesen | |
| THERMO FISHER | 618,80 | -1,43 % | 65% der untersuchten FDA-Rückschläge betrafen Produktionsstätten: Die unsichtbare Hürde für Lonza, Thermo Fisher und NeuroThera | ||
| TELADOC HEALTH | 6,986 | -1,77 % | Truist raises Teladoc stock price target to $9 on EBITDA outlook | ||
| HIMS & HERS HEALTH | 14,110 | -3,36 % | Hims & Hers Health, Inc: Hers launches free Metabolic Deep Dive to help show UK women what's really holding back their weight loss | Hers launches free Metabolic Deep Dive to help show UK women what's really holding back their weight loss
New YouGov research finds 61% of UK women are trying to lose weight, yet many are working... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,059 | 0,00 % | Sernova Biotherapeutics: 11,2 Millionen Dollar für die Fusion - und doch rutscht die Aktie | ||
| BOSTON SCIENTIFIC | 39,180 | +0,01 % | Boston Scientific Corporation: Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes | MARLBOROUGH, Mass., Nov. 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) announced today that it has priced a public offering of $3,000,000,000 aggregate principal... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,130 | 0,00 % | Geratherm Medical Aktie: Der Umbau soll die Wende bringen | Geratherm Medical steckt operativ weiter in einer schwierigen Phase. Im ersten Halbjahr 2026 sank der Umsatz um 12,5 Prozent auf 7,0 Millionen Euro, während das EBIT auf minus 0,5 Millionen Euro zurückging.... ► Artikel lesen | |
| DEXCOM | 73,40 | +0,27 % | DexCom, Inc.: Dexcom Marks Athenry Opening With Celebration of Commercial Production Milestone | Opening ceremony attended by Minister for Public Expenditure, Infrastructure, Public Service Reform and Digitalisation, Jack Chambers, TD; Minister for Enterprise, Tourism and Employment, Peter... ► Artikel lesen | |
| PAUL HARTMANN | 187,50 | -0,27 % | Januar bis September 2026: PAUL HARTMANN steigert erneut Umsatz und Ergebnis und erhöht Ergebnisprognose 2026, während 2027 von Gesundheitsreformen belastet wird | Heidenheim (ots) - - Organisches Umsatzwachstum von 3,2 %, Umsatzerlöse steigen auf 1.885,0 Mio. EUR - Bereinigtes EBITDA liegt bei 238,7 Mio. EUR und damit 42,9 Mio. EUR bzw. 21,9 % über Vorjahreswert... ► Artikel lesen | |
| CERENOME | 0,541 | -7,52 % | Cerenome outlines $10M-$12.5M 2026 gross billings run rate exit while targeting mid-2027 REYOBIQ top line data | ||
| CARDINAL HEALTH | 250,50 | +0,93 % | Wells Fargo raises Cardinal Health stock price target on pharma strength | ||
| INMODE | 11,420 | -1,34 % | InMode Ltd.: InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook | YOKNEAM, Israel, Nov. 11, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,570 | -2,48 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen |